Women with aggressive, less common type of breast cancer, known as triple negative, compared with the more common form of the disease may be different from each other by a panel of 17 small RNA molecules that are normally directly affect genetic changes.
The researchers headed by Luciani Cavalli, Ph.D., Georgetown center complex treatment Lombardi Cancer and colleagues found that differences in the expression of these small RNAs, known as microRNAs, at higher or lower levels may partly explain disparate levels of triple negative cancer breast cancer in Latin women compared to non-Hispanic white women and potentially leads to more effective treatment options.
This discovery of a new study, which was published on October 22, 2019 in Oncotarget.
"Because of the differences in miRNA expression on racial or ethnic grounds, we have determined that it is extremely important to characterize the genomic (or ancestral background) women with triple-negative breast cancer" - said Cavalli, associate professor of medicine at the Medical School at Georgetown University. . "Despite the fact that we have concentrated on the genetics, we continue to recognize that non-genetic factors, such as socio-economic conditions that may substantially affect the incidence triple Negative nym breast cancer and other breast cancer subtypes."
According to estimates of statisticians, this type of cancer is found in one-third of women in Latin America, which is higher than in the United States. Researchers have focused in particular on Brazil, where in 2018 was diagnosed about 60,000 new cases of breast cancer.
Scientists have found that in women with triple negative breast cancer have specific alterations in their gene copies, which directly affects the expression of 17 miRNAs compared with women with other forms of breast cancer, who had no such changes. They also found that the expression levels of most of these miRNAs were associated with clinical aggressiveness of the tumor (advanced degree and stage).
"MicroRNA Panel that we have defined, indicates the potential, critical pathways associated with cancer, and gene networks that can be targeted for treatment of breast cancer in Spanish women, as soon as our results are confirmed by larger studies," concluded Cavalli. "Focusing on the genetic changes that are unique biology of their tumors, can lead to more effective treatment, which can increase the life expectancy of Latin women, who do not have many therapeutic options for combating this very aggressive disease."